Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis.
Saved in:
| Title: | Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis. |
|---|---|
| Authors: | Fournier J; Department of Epidemiology and Medical Evaluation, CHU Grenoble Alpes, Grenoble, France. jfournier@chu-grenoble.fr., Boussat B; Department of Epidemiology and Medical Evaluation, CHU Grenoble Alpes, Grenoble, and Laboratory TIMC, UMR 5525, CNRS, Joseph Fourier University, Grenoble, France., Dervaux B; Department of Research and Innovation, CHRU Lille, Lille, France., Gaudin P; T-RAIG, TIMC, UMR 5525 CNRS, University of Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France., Romand X; T-RAIG, TIMC, UMR 5525 CNRS, University of Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France. |
| Source: | Clinical and experimental rheumatology [Clin Exp Rheumatol] 2025 Jan; Vol. 43 (1), pp. 62-69. Date of Electronic Publication: 2024 Oct 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
